The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosisLennart Lenk, Denis M. Schewe, Frédérique Corallo et al.|Blood|2024Cited by 20
Molecular complete remission following combination treatment of daratumumab and venetoclax in an adolescent with relapsed mixed phenotype acute leukemiaMartin Stanulla, Britta Maecker‐Kolhoff, Denis M. Schewe et al.|Annals of Hematology|2023Cited by 7
Prognostic Role of Kidney Disease in Newly Diagnosed Acute Myeloid Leukemia Under Venetoclax-Based Low-Intensity TherapyKatja Krüger, Rabia Shahswar, Razif Gabdoulline et al.|Cancers|2025Cited by 2
Intra-subtype heterogeneity shapes treatment response in <i>KMT2A</i> -rearranged ALL across all age groupsAlina Hartmann, Claudia D. Baldus, Lorenz Bastian et al.|bioRxiv (Cold Spring Harbor Laboratory)|2025Cited by 1